These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

101 related items for PubMed ID: 8077983

  • 1. Activity of BAY y 3118, a novel 4-quinolone, against Brucella melitensis.
    García-Rodríguez JA, García-Sánchez JE, Trujillano-Martín I, García-Sánchez E, García-García MI, Fresnadillo MJ.
    J Chemother; 1994 Apr; 6(2):102-6. PubMed ID: 8077983
    [Abstract] [Full Text] [Related]

  • 2. [Short communication: Investigation of in vitro antibiotic susceptibility of Brucella melitensis].
    Alişkan H, Turunç T, Demiroğlu YZ, Colakoğlu S, Arslan H.
    Mikrobiyol Bul; 2008 Jan; 42(1):125-9. PubMed ID: 18444570
    [Abstract] [Full Text] [Related]

  • 3. The in-vitro activity of Bay y 3118, a new chlorofluoroquinolone.
    Wise R, Andrews JM, Brenwald N.
    J Antimicrob Chemother; 1993 Jan; 31(1):73-80. PubMed ID: 8383104
    [Abstract] [Full Text] [Related]

  • 4. Susceptibilities of Brucella melitensis isolates to clinafloxacin and four other new fluoroquinolones.
    García-Rodríguez JA, García Sánchez JE, Trujillano I, García Sánchez E, García García MI, Fresnadillo MJ.
    Antimicrob Agents Chemother; 1995 May; 39(5):1194-5. PubMed ID: 7625815
    [Abstract] [Full Text] [Related]

  • 5. In vitro activities of various antimicrobials against Brucella melitensis strains in the Aegean region in Turkey.
    Yamazhan T, Aydemir S, Tünger A, Serter D, Gökengin D.
    Med Princ Pract; 2005 May; 14(6):413-6. PubMed ID: 16220015
    [Abstract] [Full Text] [Related]

  • 6. In vitro activities of new quinolones against Brucella melitensis isolated in a tertiary-care hospital in Turkey.
    Kocagöz S, Akova M, Altun B, Gür D, Hasçelik G.
    Clin Microbiol Infect; 2002 Apr; 8(4):240-2. PubMed ID: 12047416
    [Abstract] [Full Text] [Related]

  • 7. Comparative in-vitro activities of the new quinolone, Bay y 3118, and ciprofloxacin, sparfloxacin, tosufloxacin, CI-960 and CI-990.
    Bauernfeind A.
    J Antimicrob Chemother; 1993 Apr; 31(4):505-22. PubMed ID: 7605398
    [Abstract] [Full Text] [Related]

  • 8. In vitro activity of tigecycline, tetracycline and fluoroquinolones against Brucella melitensis.
    Kilic S, Dizbay M, Cabadak H.
    J Chemother; 2008 Feb; 20(1):33-7. PubMed ID: 18390405
    [Abstract] [Full Text] [Related]

  • 9. Comparative in vitro activities of ofloxacin, difloxacin, ciprofloxacin, and other selected antimicrobial agents against Brucella melitensis.
    Khan MY, Dizon M, Kiel FW.
    Antimicrob Agents Chemother; 1989 Aug; 33(8):1409-10. PubMed ID: 2802568
    [Abstract] [Full Text] [Related]

  • 10. Susceptibility of Salmonella typhi and Brucella melitensis to the new fluoroquinolone rufloxacin (MF 934).
    Qadri SM, Ayub A, Ueno Y, Saldin H.
    Chemotherapy; 1993 Aug; 39(5):311-4. PubMed ID: 8396527
    [Abstract] [Full Text] [Related]

  • 11. Anti-Brucella activity of Ro 23-9424, a dual-action antibacterial.
    Qadri SM, Ueno Y, Ayub A.
    Chemotherapy; 1993 Aug; 39(6):386-9. PubMed ID: 8222864
    [Abstract] [Full Text] [Related]

  • 12. Increased activity of a new chlorofluoroquinolone, BAY y 3118, compared with activities of ciprofloxacin, sparfloxacin, and other antimicrobial agents against anaerobic bacteria.
    Aldridge KE.
    Antimicrob Agents Chemother; 1994 Jul; 38(7):1671-4. PubMed ID: 7979307
    [Abstract] [Full Text] [Related]

  • 13. In vitro activity of BAY y 3118, and nine other antimicrobial agents against anaerobic bacteria.
    García-Rodríguez JA, García-Sánchez JE, Trujillano-Martín I, García-Sánchez E, García-García MI, Fresnadillo-Martínez MJ.
    J Chemother; 1995 Jun; 7(3):189-96. PubMed ID: 7562012
    [Abstract] [Full Text] [Related]

  • 14. In-vitro activity of four new fluoroquinolones.
    García-Rodríguez JA, García Sánchez JE, García García MI, Fresnadillo MJ, Trujillano I, García Sánchez E.
    J Antimicrob Chemother; 1994 Jul; 34(1):53-64. PubMed ID: 7961215
    [Abstract] [Full Text] [Related]

  • 15. Susceptibility of Brucella melitensis to fluoroquinolones.
    Qadri SM, Akhtar M, Ueno Y, al-Sibai MB.
    Drugs Exp Clin Res; 1989 Jul; 15(10):483-5. PubMed ID: 2632216
    [Abstract] [Full Text] [Related]

  • 16. In vitro activities of six new fluoroquinolones against Brucella melitensis.
    Trujillano-Martín I, García-Sánchez E, Martínez IM, Fresnadillo MJ, García-Sánchez JE, García-Rodríguez JA.
    Antimicrob Agents Chemother; 1999 Jan; 43(1):194-5. PubMed ID: 9869594
    [Abstract] [Full Text] [Related]

  • 17. Antibacterial activity of lomefloxacin against Brucella melitensis.
    Qadri SM, al-Sedairy S, Ueno Y.
    Diagn Microbiol Infect Dis; 1990 Jan; 13(3):277-9. PubMed ID: 2383977
    [Abstract] [Full Text] [Related]

  • 18. Susceptibility of Brucella melitensis to the new fluoroquinolone PD 131628: comparison with other drugs.
    Qadri SM, Ueno Y.
    Chemotherapy; 1993 Jan; 39(2):128-31. PubMed ID: 8384544
    [Abstract] [Full Text] [Related]

  • 19. [In vitro activity of sparfloxacin against methicillin-resistant staphylococci].
    Wallrauch C, Voss A, Milatovic D, Braveny I.
    Arzneimittelforschung; 1995 Jun; 45(6):723-5. PubMed ID: 7646580
    [Abstract] [Full Text] [Related]

  • 20. In-vitro activity of sparfloxacin, a new quinolone antimicrobial agent.
    Cooper MA, Andrews JM, Ashby JP, Matthews RS, Wise R.
    J Antimicrob Chemother; 1990 Nov; 26(5):667-76. PubMed ID: 2079449
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.